Zealand Pharma Release: Completion Of Exercise In Full Of Overallotment Option Of 15%

Published: Aug 18, 2017

Company announcement - No. 38/2017

  • Zealand Pharma A/S has today registered a capital increase of 156,250 new shares as completion of exercise in full of overallotment option of 15%


Copenhagen, August 18, 2017 - With reference to the company announcements no. 37/2017, dated August 15, 2017 regarding the exercise in full of overallotment option of 15% by Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, Zealand Pharma A/S ("Zealand") announces that it has today registered an increase of its share capital by nominally DKK 156,250 divided into 156,250 new shares with a nominal value of DKK 1 each (the "New Shares") with the Danish Business Authority.

Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 30,718,652 divided into 30,718,652 shares with a nominal value of DKK 1 each.

The New Shares rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The New Shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen on August 21, 2017 in the permanent ISIN code DK0060257814.

This company announcement does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC are acting as joint book-running managers, and Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-lead managers for the offering referred to herein. Copies of the preliminary U.S. prospectus and the final U.S. prospectus relating to the Offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: +1-866-471-2526, facsimile: +1 212-902-9316, or e-mail: prospectus-ny@ny.email.gs.com.


For further information, please contact:

Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

Important information
No announcements or information regarding the initial public offering may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of shares or American Depositary Shares ("ADSs") in any jurisdiction where such steps would be required. The issue or sale of ADSs, and the subscription for or purchase of ADSs, are subject to special legal or statutory restrictions in certain jurisdictions. Zealand is not liable if these restrictions are not complied with by any other person.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL; Nasdaq Global Select Market: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines.
Zealand is based in Copenhagen (Glostrup), Denmark.

Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as on the offering of ADSs in the United States and the issue and listing in Denmark of the shares underlying the ADSs that provide our expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/804dedb1-3a9b-4518-9627-9137ad530c15

Back to news